Han Song, Qu Fang-Wen, Wang Peng-Fei, Liu Ying-Xin, Li Shou-Wei, Yan Chang-Xiang
Department of Neurosurgery, Sanbo Brain Hospital, Capital Medical University, Beijing, China.
Grade 2018, Medical College, Qingdao University, Qingdao, China.
Front Surg. 2022 Apr 13;9:803237. doi: 10.3389/fsurg.2022.803237. eCollection 2022.
Diffused gliomas are aggressive malignant brain tumors. Various hematological factors have been proven to predict the prognosis of patients with gliomas. The aim of this study is to integrate these hematological markers and develop a comprehensive system for predicting the prognosis of patients with gliomas.
This retrospective study included 723 patients pathologically diagnosed with diffused gliomas. Hematological indicators were collected preoperatively, including neutrophil-to-lymphocyte ratio (NLR), lymphocyte-monocyte ratio (LMR), platelet-to-lymphocyte ratio (PLR), albumin globulin ratio (AGR), platelet distribution width (PDW), red blood cell distribution width (RDW), fibrinogen (FIB), and prognostic nutritional index (PNI). Least absolute shrinkage and selection operator (LASSO) Cox was applied to screen the hematological indicators for a better prediction of patients' prognosis and to build an inflammation-nutrition score. A nomogram model was developed to predict the overall survival (OS), which included age, tumor grade, IDH-1 mutations, and inflammation-nutrition score.
Patients were randomly divided into a primary cohort ( = 509) and a validation cohort ( = 214). There was no difference in age and IDH-1 mutation frequency between the cohorts. In the primary cohort, NLR, LMR, AGR, FIB, and PNI were selected to build an inflammation nutrition score. Patients with a high-risk inflammation-nutrition score had a short median OS of 17.40 months compared with 27.43 months in the low-risk group [ 2.54; 95% (1.91-3.37); < 0.001]. Moreover, age, tumor grade, IDH-1 mutations, and inflammation-nutrition score were independent prognostic factors in the multivariate analysis and thus were included in the nomogram model. The nomogram model showed a high prediction value with a Harrell's concordance index (C-index) of 0.75 [95% (0.72-0.77)]. The validation cohort supported these results.
The prognostic nomogram model provided a high prognostic predictive power for patients with gliomas.
弥漫性胶质瘤是侵袭性恶性脑肿瘤。多种血液学因素已被证实可预测胶质瘤患者的预后。本研究的目的是整合这些血液学标志物,开发一个综合系统来预测胶质瘤患者的预后。
这项回顾性研究纳入了723例经病理诊断为弥漫性胶质瘤的患者。术前收集血液学指标,包括中性粒细胞与淋巴细胞比值(NLR)、淋巴细胞与单核细胞比值(LMR)、血小板与淋巴细胞比值(PLR)、白蛋白球蛋白比值(AGR)、血小板分布宽度(PDW)、红细胞分布宽度(RDW)、纤维蛋白原(FIB)和预后营养指数(PNI)。应用最小绝对收缩和选择算子(LASSO)Cox回归筛选血液学指标以更好地预测患者预后,并构建炎症-营养评分。开发了一个列线图模型来预测总生存期(OS),该模型包括年龄、肿瘤分级、异柠檬酸脱氢酶-1(IDH-1)突变和炎症-营养评分。
患者被随机分为初级队列(n = 509)和验证队列(n = 214)。两个队列之间的年龄和IDH-1突变频率没有差异。在初级队列中,选择NLR、LMR、AGR、FIB和PNI来构建炎症-营养评分。高风险炎症-营养评分的患者中位总生存期较短,为17.40个月,而低风险组为27.43个月[比值比(OR)= 2.54;95%置信区间(CI)(1.91 - 3.37);P < 0.001]。此外,在多因素分析中,年龄、肿瘤分级、IDH-1突变和炎症-营养评分是独立的预后因素,因此被纳入列线图模型。列线图模型显示出较高的预测价值,Harrell一致性指数(C指数)为0.75 [95% CI(0.72 - 0.77)]。验证队列支持了这些结果。
预后列线图模型为胶质瘤患者提供了较高的预后预测能力。